These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3220 related articles for article (PubMed ID: 32272481)

  • 21. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.
    Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
    Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
    Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design.
    Meyer-Almes FJ
    Comput Biol Chem; 2020 Oct; 88():107351. PubMed ID: 32769050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
    Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
    J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and Computational Approach of Selected Phytocompounds from
    Rakib A; Paul A; Chy MNU; Sami SA; Baral SK; Majumder M; Tareq AM; Amin MN; Shahriar A; Uddin MZ; Dutta M; Tallei TE; Emran TB; Simal-Gandara J
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32872217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
    Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
    Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.
    Sies H; Parnham MJ
    Free Radic Biol Med; 2020 Aug; 156():107-112. PubMed ID: 32598985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2.
    Tripathi PK; Upadhyay S; Singh M; Raghavendhar S; Bhardwaj M; Sharma P; Patel AK
    Int J Biol Macromol; 2020 Dec; 164():2622-2631. PubMed ID: 32853604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.
    Brown AS; Ackerley DF; Calcott MJ
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an
    Ferraz WR; Gomes RA; S Novaes AL; Goulart Trossini GH
    Future Med Chem; 2020 Oct; 12(20):1815-1828. PubMed ID: 32787684
    [No Abstract]   [Full Text] [Related]  

  • 38. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.
    Jin Z; Zhao Y; Sun Y; Zhang B; Wang H; Wu Y; Zhu Y; Zhu C; Hu T; Du X; Duan Y; Yu J; Yang X; Yang X; Yang K; Liu X; Guddat LW; Xiao G; Zhang L; Yang H; Rao Z
    Nat Struct Mol Biol; 2020 Jun; 27(6):529-532. PubMed ID: 32382072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M
    Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D
    Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
    Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ
    Nat Commun; 2020 Aug; 11(1):4282. PubMed ID: 32855413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 161.